[molongui_author_posts count=100 list_divider=”yes” show_date=”yes”]
Church of Psilomethoxin, Part 1: Sacramental Skepticism. Is the Church in Denial?
This is the first article in a series investigating the Church of Psilomethoxin (CoP), exploring the recent debate about the Church's sacrament and the people involved in promoting the Church and its claims.
The Church of Psilomethoxin Part 2: Unraveling the Sacred Chemistry
Psymposia’s investigation into the Church of Psilomethoxin (CoP) turns to the Church’s claims that it’s currently “scientifically impossible” to test for psilomethoxin. Psychedelic chemist David Nichols calls that claim “completely nonsensical and nonscientific.
Church of Psilomethoxin, Part 3: Matters of Faith. Father, Son, and Wholly Dosed?
The Church of Psilomethoxin now admits that its claims about psilomethoxin are solely based on faith. But how strong are the religious convictions of the Church?
Church of Psilomethoxin, Part 4: The Church That Cried Capitalism
The Church of Psilomethoxin claims it’s the victim of “psychedelic capitalism,” but almost everything it claims is wrong.
Psychedelic Science 2023 Contract Muzzles Speakers: Two Clauses Dictate What Presenters Can and Can’t Say
In order to present at Psychedelic Science 2023, speakers must agree to two out-of-the-ordinary requests about content exclusivity and MAPS’ reputation.
Every Disclosed Conflict of Interest at Psychedelic Science 2023
All the financial conflict disclosures from Psychedelics Science 2023 speakers, in one handy list.
Psymposia’s Response to Heroic Hearts’ Pharma-Backed Press Conference
Veterans deserve the highest quality treatment for PTSD. It’s unacceptable and dangerous to use veterans as guinea pigs for a big pharma profit grab without resolving safety and efficacy concerns.
Correcting the Record: What The New York Times Got Wrong
In response to the The New York Times February 4 article, "How a Leftist Activist Group Helped Torpedo a Psychedelic Therapy," Psymposia requested corrections to numerous errors and false accusations.
Correcting the Record: Addressing The New York Times’ Deceptive Coverage of Psymposia
Rather than unpacking the actual causes of Lykos Therapeutics' disastrous Phase 3 trials and FDA rejection, The New York Times produced a work of fictitious propaganda that prioritizes corporate interests over public health.
The Psychedelic Syndicate: Part 1
Part 1 of The Psychedelic Syndicate reveals how the Psychedelic Science Funders Collaborative (PSFC) — a wealthy network of Silicon Valley elites and Burning Man devotees — systematically captured the psychedelic movement by influencing MAPS, funding its subsidiary Lykos’ MDMA clinical trials, and promoting underground therapy through state legalization initiatives.